Exhibit 99.2
Sage Therapeutics to Provide Business Updates at
42nd Annual J.P. Morgan Healthcare Conference
Excitement over December 2023
launch of ZURZUVAE (zuranolone), the first and only oral treatment indicated for adults with postpartum depression (PPD)
Continued progress on clinical pipeline, with topline data expected from multiple ongoing Phase 2 trials across 2024
Catalyst rich year supported by strong financial foundation and focused execution
CAMBRIDGE, Mass. January 8, 2024 Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading
the way to create a world with better brain health, today announced that Chief Executive Officer Barry Greene will discuss the Companys key business drivers for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco,
California.
As part of this presentation, Mr. Greene will discuss commercialization of
ZURZUVAE (zuranolone), the first and only once-daily 14-day oral treatment option for adults with PPD and will provide an update on the Companys
progress in advancing its brain health pipeline.
The landmark FDA approval of ZURZUVAE has fueled additional momentum in recognizing the urgency to
treat PPD, which reenforces our belief that all women with PPD who are prescribed ZURZUVAE should be able to access it. While early, we are encouraged by the positive engagement we have had in the initial launch weeks, and we believe we are off to a
great start patients are being prescribed ZURZUVAE by multiple specialties, including OBGYNs, and we are seeing enthusiasm from prescribers to learn more, said Barry Greene, CEO at Sage Therapeutics. We are also making progress
across our pipeline and look forward to several clinical data milestones in the dalzanemdor (SAGE-718) and SAGE-324 programs this year. We head into 2024 poised for a
catalyst-rich year further supported by a strong financial foundation and focused execution plans.
Commercial availability of ZURZUVAE (zuranolone) underway to support women with PPD
Sage and its collaborator, Biogen, are focused
on establishing ZURZUVAE as the first line therapy and standard of care for women with PPD. The companies recently announced commercial availability of ZURZUVAE and the specialty pharmacy distribution model by which ZURZUVAE is shipped directly to
patients who are prescribed the treatment. Sage and Biogen field sales teams are engaging in promotional dialogues with health care professionals (HCPs) who actively identify and treat women with PPD. Since commercial availability, HCPs, including
OBGYNs, psychiatrists, and primary care physicians have started to prescribe ZURZUVAE in this indication. The companies are continuing active discussions with national, regional and government payors to advocate for broad and equitable access to
ZURZUVAE for women with PPD with minimal restrictions and expect formulary discussions to continue over the course of 2024.
Innovative brain health
pipeline with potential for significant value creation
Sage is advancing a portfolio of early-stage and clinical programs featuring internally
discovered novel chemical entities targeting the GABAA and NMDA receptor systems. The Company expects several clinical data milestones in 2024 for dalzanemdor
(SAGE-718) and SAGE-324.
Dalzanemdor
(SAGE-718), the Companys first-in-class NMDA receptor positive allosteric modulator (PAM), is in development as a
potential oral therapy for cognitive disorders associated with NMDA receptor dysfunction, including Huntingtons disease (HD), Alzheimers disease (AD) and Parkinsons disease (PD). In Q4 2023, the FDA granted Orphan Drug Designation
to SAGE-718 for the treatment of HD, and the United States Adopted Name (USAN) Council assigned the nonproprietary name of dalzanemdor to this compound.
1